|
🎓
|
| Location |
Boston, MA, USA |
| Type |
Private Research University |
| Founded |
1839 |
| Website |
https://www.bu.edu |
| Focus Areas |
[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), CTE, ALS |
| Departments |
School of Medicine, Neurology Department, Alzheimer's Disease Center, CTE Center |
Boston University (BU) is a leading private research university located in Boston, Massachusetts. Founded in 1839, BU is one of the largest independent nonprofit institutions of higher education in the United States, with over 37,000 students across 17 schools and colleges. The university is particularly renowned for its neuroscience and neurodegeneration research programs through the BU School of Medicine and the Center for Neuroscience Research[@bu2026].
The institution is recognized for its contributions to neurodegenerative disease research, with focus areas including Alzheimer's Disease, Parkinson's Disease, Chronic Traumatic Encephalopathy (CTE), and ALS. BU maintains an NIH-funded Alzheimer's Disease Research Center and houses the world-renowned CTE Center.
BU researchers have made pioneering contributions to understanding the mechanisms of neurodegeneration, developing novel therapeutics, and advancing clinical care for patients with memory disorders and movement disorders. The institution's impact spans basic science discovery, translational research, clinical trials, and public health initiatives.
¶ History and Institutional Background
Boston University has evolved significantly since its founding in 1839 as a small Methodist college. The university grew into a major research institution over the following decades, with particularly significant expansion in the health sciences.
The neuroscience program has expanded substantially since the 1980s, with remarkable growth in neurodegeneration research following the establishment of the Alzheimer's Disease Research Center in 1996. The CTE Center was established in the 2000s and has become the world's leading program for research on this devastating disease.
Historical achievements associated with the neurology department include the discovery of phenytoin for epilepsy patients at Boston City Hospital (the predecessor to Boston Medical Center). Notable historical figures include Derek Denny-Brown, Norman Geschwind, Houston Merritt, James Putnam, William Lenox, and Raymond Adams—pioneers who shaped the field of neurology.
BU houses an NIH-funded Alzheimer's Disease Research Center that focuses on multiple research domains:
- Early Detection and Biomarkers: Development of novel CSF and blood biomarkers for early detection of Alzheimer's disease
- Clinical Trials: Phase I-III trials for disease-modifying therapies
- Lifestyle Factors: Investigation of lifestyle factors in cognitive decline and dementia prevention
- Health Disparities: Research on health disparities in Alzheimer's disease affecting underserved populations
- Neuroimaging: Advanced MRI and PET imaging for understanding disease progression
The BU CTE Center is world-renowned for research on Chronic Traumatic Encephalopathy, a progressive neurodegenerative disease caused by repetitive head trauma. Under the leadership of Dr. Ann McKee and Dr. Bob Stern, the center has:
- Characterized the clinical and pathological features of CTE
- Developed diagnostic criteria for the disease
- Established brain bank resources for research
- Conducted longitudinal studies of athletes and military veterans
BU houses the cerebrovascular research component of the Framingham Heart Study, one of the most influential epidemiological studies in history. The multi-generational study has been running for over 70 years and has pioneered:
- Stroke neuroimaging research
- Understanding of vascular contributions to dementia
- Risk factor identification for cognitive decline
- Development of cardiovascular risk assessment tools
The Center for Neuroscience Research brings together investigators studying fundamental mechanisms of neurodegeneration:
- Synaptic Function and Dysfunction: Research on how synapses are affected in neurodegenerative diseases
- Neuroinflammation: Investigation of the role of immune activation in neurodegeneration
- Protein Aggregation: Studies on alpha-synuclein, tau, and amyloid-beta aggregation mechanisms
- Neural Circuit Function: Understanding how neural circuits are compromised in disease
The BU School of Medicine Neurology Department conducts research across multiple neurological conditions:
- Alzheimer's disease and related dementias
- Parkinson's disease and movement disorders
- Amyotrophic lateral sclerosis (ALS)
- Multiple sclerosis
- Stroke and vascular cognitive impairment
- Epilepsy
- Neuromuscular diseases
¶ Key Researchers and Leadership
Dr. Ann McKee is a world-renowned neuropathologist and Director of the BU CTE Center. Her research has fundamentally changed understanding of CTE and its relationship to repetitive head trauma. She has characterized the neuropathological features of CTE and established diagnostic criteria used worldwide.
Dr. Bob Stern serves as Director of Clinical Research for the CTE Center and has led numerous studies on CTE biomarkers and clinical manifestations. His work has focused on developing methods for diagnosing CTE in living individuals and understanding disease progression.
Dr. Benjamin Wolozin is a professor in the Department of Pharmacology and Pharmaceutical Sciences at BU. His laboratory studies protein aggregation in neurodegeneration, with a focus on understanding the mechanisms of alpha-synuclein and tau aggregation and developing therapeutic interventions.
¶ Andrew Budson, MD
Dr. Andrew Budson is a leading researcher in Alzheimer's disease clinical research, focusing on memory and cognitive disorders. His work has contributed to understanding memory dysfunction and developing approaches for differential diagnosis of memory disorders.
Dr. David M. Greer serves as Professor and Chair of the Department of Neurology, providing leadership for the department's comprehensive research programs.
BU provides comprehensive diagnostic and treatment services for neurodegenerative diseases through its clinical network:
- Memory Disorders Clinic: Comprehensive evaluation for Alzheimer's disease and related conditions
- Movement Disorders Program: Care for Parkinson's disease and related conditions
- CTE Program: Specialized evaluation for individuals with history of repetitive head trauma
- ALS Clinic: Multidisciplinary care for patients with amyotrophic lateral sclerosis
- Multiple Sclerosis Center: Comprehensive MS care and research
- Stroke Program: Prevention, treatment, and rehabilitation for stroke and vascular cognitive impairment
BU maintains advanced neuroimaging facilities including:
- MRI Suite: State-of-the-art 3T and 7T MRI scanners for structural, functional, and diffusion tensor imaging
- PET Imaging: PET facilities for amyloid, tau, and other neurodegenerative disease biomarkers
- CTE-specific Protocols: Specialized imaging protocols for CTE research
- Flow Cytometry Core: Analysis of immune cell populations in neurodegeneration
- Genomics Core: Next-generation sequencing capabilities for genetic studies
- Protein Core: Expression and purification of proteins involved in aggregation
- Cell Culture Facilities: BSL-2 laboratories for cell biology studies
BU researchers utilize various animal models for neurodegeneration research:
- Transgenic mouse models of Alzheimer's disease (APP/PS1, 3xTg-AD)
- Alpha-synuclein transgenic and viral vector models of Parkinson's disease
- SOD1 and TDP-43 models for ALS research
- Zebrafish models for developmental neuroscience
- Rodent models of traumatic brain injury for CTE research
BU researchers have made pioneering contributions to neurodegenerative disease research:
Dr. Wolozin's laboratory discovered novel mechanisms of alpha-synuclein and tau aggregation, identifying key molecular pathways that lead to protein misfolding and aggregation. These discoveries have led to identification of new therapeutic targets for Parkinson's disease and Alzheimer's disease.
The CTE Center has been instrumental in characterizing the neuropathology of CTE, demonstrating the disease is distinct from Alzheimer's disease, and identifying unique features including preferential accumulation of tau in neurons around blood vessels.
The BU Alzheimer's Disease Center leads Phase I-III clinical trials for disease-modifying therapies, testing novel pharmacological interventions in early-stage Alzheimer's disease and related conditions.
Novel CSF and blood biomarkers developed at BU enable early detection of Alzheimer's and Parkinson's diseases, supporting early diagnosis and monitoring of disease progression.
Research through the Framingham Heart Study has identified major vascular risk factors for dementia and established the link between cardiovascular health and cognitive decline.
BU offers comprehensive training opportunities in neurodegenerative disease research:
- Neuroscience PhD Program: Training in molecular, cellular, and systems neuroscience
- MD/PhD Track: For physician-scientists pursuing neurodegeneration research
- Graduate Program in Neuroscience: Comprehensive training in all aspects of neuroscience
- Neurology Residency: Four-year training program preparing the next generation of neurologists
- Behavioral Neurology Fellowship: Specialized training in dementia care and research
- Movement Disorders Fellowship: Training in Parkinson's disease and related conditions
- Postdoctoral Research Fellowships: World-class postdoctoral fellowships in leading laboratories
- Clinical Research Training: K12 and T32 programs for clinical investigators
BU is committed to addressing health disparities in neurodegenerative disease:
- Research on disparities in Alzheimer's disease affecting African American and Hispanic populations
- Community outreach programs to increase research participation among underrepresented groups
- Studies on socioeconomic factors affecting dementia care
- Development of culturally appropriate assessment tools
BU maintains collaborative relationships with leading international institutions:
- University of Oxford: Joint studies on tau pathology
- University of Cambridge: Biomarker validation studies
- Karolinska Institute: Parkinson's disease genetics collaboration
- McGill University: Frontotemporal dementia research
- University of Glasgow: CTE research collaboration
BU currently hosts multiple active clinical trials for neurodegenerative diseases:
- Disease-modifying therapies for early-stage Alzheimer's disease
- Novel interventions for mild cognitive impairment
- Anti-amyloid and anti-tau therapeutic approaches
- Lifestyle intervention studies
Current strategic priorities for BU neurodegeneration research include:
- Clinical Trials Infrastructure: Expansion of clinical trials capacity for Alzheimer's and Parkinson's disease
- Biomarker Development: Novel biomarkers using proteomics and metabolomics approaches
- Computational Neuroscience: Creation of a center for computational approaches to brain disease
- Diversity Enhancement: Increasing diversity in clinical trial participation
- Precision Medicine: Development of personalized approaches to neurodegeneration treatment
The Vascular Neurology Program at BU investigates the relationship between cerebrovascular disease and cognitive decline:
- Stroke Prevention: Studies on modifiable risk factors for stroke and vascular dementia
- Neuroimaging of Vascular Changes: Advanced imaging to characterize vascular contributions to cognitive impairment
- Rehabilitation Research: Approaches to recovery after stroke and vascular cognitive impairment
- White Matter Disease: Research on small vessel disease and its impact on cognition
The Neuromuscular Program focuses on diseases affecting peripheral nerves and muscles:
- ALS Research: Genetic mechanisms and therapeutic development for amyotrophic lateral sclerosis
- Peripheral Neuropathy: Studies on diabetic and inherited peripheral neuropathies
- Myasthenia Gravis: Investigation of autoimmune mechanisms in neuromuscular junction disorders
¶ Sleep and Circadian Research
BU researchers study the relationship between sleep disorders and neurodegenerative diseases:
- REM Sleep Behavior Disorder: Investigation of RBD as an early marker of synucleinopathies
- Sleep Apnea: Studies on the relationship between sleep-disordered breathing and cognitive decline
- Circadian Dysfunction: Research on how circadian rhythm disruptions affect neurodegeneration
¶ Community Engagement and Public Health
BU provides extensive public education resources:
- Community Lectures: Regular talks on brain health, memory preservation, and dementia prevention
- Memory Screening Programs: Free memory assessments for community members
- Caregiver Support: Resources and support programs for families caring for patients with dementia
- Patient Navigation Services: Guidance through diagnostic and treatment processes
- Support Groups: Regular meetings for patients and caregivers
- Educational Materials: Written and video resources on living with neurodegenerative conditions
- Advance Care Planning: Guidance on planning for future care needs
¶ Funding and Support
BU's neurodegenerative disease research is funded by multiple sources:
- NIH National Institute on Aging (NIA): Primary funder through the ADRC grant
- NIH National Institute of Neurological Disorders and Stroke (NINDS): Support for CTE, Parkinson's, and ALS research
- NIH National Institute of Child Health and Human Development: CTE research funding
- Alzheimer's Association: Research grants and fellowship support
- Michael J. Fox Foundation: Parkinson's disease research funding
- ALS Association: Support for ALS research and care
- Department of Defense: CTE research funding through the Chronic Effects of Neurotrauma Consortium
BU maintains strategic partnerships with pharmaceutical companies for clinical trial conduct and biomarker validation studies.
¶ Scientific Resources and Cores
The BU Brain Bank provides postmortem brain tissue for research:
- CTE brain specimens
- Alzheimer's disease tissue
- Parkinson's disease tissue
- Normal aging control tissue
- Longitudinal clinical data from Framingham Heart Study
- Imaging datasets from CTE research
- Clinical trial data from ADRC studies
- Genetic data from family studies
- Continuing Medical Education: Courses for healthcare providers on dementia diagnosis and management
- Annual Neurology Symposium: State-of-the-art reviews for clinicians and researchers
- Workshop Programs: Hands-on training in neuroimaging and other techniques
- Science Fair Judging: BU researchers mentor and judge local science fairs
- Brain Awareness Week: Educational programs for local schools
- Teacher Training: Professional development for science teachers
- Pipeline Programs: Programs to encourage underrepresented minorities to pursue neuroscience careers
- Summer Research Programs: Research experiences for undergraduate students
- Postbaccalaureate Programs: Training opportunities for students from diverse backgrounds
¶ Quality Metrics and Impact
- Peer-reviewed publications: Over 150 publications annually from neurology faculty
- Citation impact: BU neurodegeneration research is highly cited nationally
- Clinical trial enrollment: Thousands of participants enrolled in clinical studies
- Fellows trained: Dozens of postdoctoral fellows have completed training
- Faculty placements: Trainees have obtained faculty positions at leading institutions
- Community impact: Thousands of patients evaluated annually
BU is developing precision medicine approaches for neurodegeneration:
- Genetic Counseling: Integration of genetic testing into clinical practice
- Personalized Biomarker Profiles: Individualized biomarker panels for disease monitoring
- Targeted Therapeutics: Research on gene-specific and pathway-specific treatments
- Remote Monitoring: Technologies for monitoring patients at home
- Cognitive Apps: Digital tools for cognitive assessment and training
- Wearable Devices: Technology for detecting early cognitive changes
- Lifestyle Interventions: Studies on the impact of exercise, diet, and cognitive stimulation on brain health
- Risk Factor Modification: Research on modifiable risk factors for dementia
- Early Intervention: Programs to identify and treat individuals at risk before symptoms appear
Boston Medical Center (BU's teaching hospital) provides clinical infrastructure:
- Inpatient neurology services
- Outpatient specialty clinics
- Community health programs
- Safety-net healthcare for underserved populations
The VA Boston Healthcare System supports research and clinical care:
- Veteran-focused neurodegenerative disease research
- Clinical trials for veteran populations
- PTSD and TBI research related to CTE
BU maintains relationships with multiple affiliated hospitals:
- Beth Israel Deaconess Medical Center
- Cambridge Health Alliance
- Lahey Hospital and Medical Center